Advertisement

Sex and the patient with cardiovascular risk factors: focus on sildenafil

  • Robert A Kloner
    Correspondence
    Requests for reprints should be addressed to Robert A. Kloner, MD, PhD, The Heart Institute, Good Samaritan Hospital, 1225 Wilshire Boulevard, Los Angeles, California 90017
    Footnotes
    Affiliations
    The Heart Institute, Good Samaritan Hospital, and the Department of Medicine, University of Southern California, Los Angeles, California, USA
    Search for articles by this author
  • Author Footnotes
    1 Robert A. Kloner, MD, PhD, is a researcher, consultant, and speaker for Pfizer Inc.

      Abstract

      Erectile dysfunction (ED) is common in men with cardiovascular disease. The introduction of sildenafil citrate, the first oral agent for the treatment of this disorder, has increased awareness about the risks of sexual activity in cardiac patients and raised concerns about the safety of sildenafil in patients being treated for coronary disease. Sildenafil is a potent and selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for the degradation of cyclic guanosine monophosphate (cGMP). Sildenafil acts along the same general pathway as nitric oxide donors to increase cGMP levels and enhance erections. Sildenafil is a modest vasodilator that causes small decreases in systemic arterial pressure and mild preload and afterload reductions. It does not cause major decreases in blood pressure when administered with one or more standard antihypertensive agents. Because PDE5 is also present in small amounts in the systemic vasculature, sildenafil can cause a synergistic and major decrease in pressure when combined with organic nitrates. Use of organic nitrates is the only contraindication to sildenafil use. Data on sildenafil in patients with recent (less than 6 months) myocardial infarction (MI), unstable angina, stroke, and recent life-threatening arrhythmias are not available, so the drug should be used with caution in patients with unstable cardiac conditions. Placebo-controlled and open-label phase 2/3 trials including men with ischemic heart disease did not show an increase in MI or serious cardiovascular events in patients treated with sildenafil versus placebo. None of the serious cardiovascular events reported in these trials were considered treatment related by the investigators. There is a small but finite increased risk of developing ischemia or infarction with sexual activity. Therefore, before prescribing sildenafil or any current or future treatment for ED to patients with known cardiac disease or multiple cardiovascular risk factors, physicians should discuss the potential cardiac risk of sexual activity and perform a complete medical assessment, including an exercise stress test if appropriate.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Qureshi A.I
        • Giles W.H
        • Croft J.B
        Impaired glucose tolerance and the likelihood of nonfatal stroke and myocardial infarction.
        Stroke. 1998; 29: 1329-1332
        • O’Donnell C.J
        • Ridker P.M
        • Glynn R.J
        • et al.
        Hypertension and borderline isolated systolic hypertension increase risks of cardiovascular disease and mortality in male physicians.
        Circulation. 1997; 95: 1132-1137
        • Kannel W.B
        The Framingham Study.
        J Atheroscler Thromb. 2000; 6: 60-66
        • Feldman H.A
        • Goldstein I
        • Hatzichristou D.G
        • Krane R.J
        • McKinlay J.B
        Impotence and its medical and psychosocial correlates.
        J Urol. 1994; 151: 54-61
        • Mittleman M.A
        • Siscovick D.S
        Physical exertion as a trigger of myocardial infarction and sudden cardiac death.
        Cardiol Clin. 1996; 14: 263-270
      1. Muller JE, Mittleman MA, Maclure M, Sherwood JB, Tofler GH, for the Determinants of Myocardial Infarction Onset Study Investigators. Triggering myocardial infarction by sexual activity: low absolute risk and prevention by regular physical exertion. JAMA. 1996;275:1405–1409.

        • Kloner R.A
        • Zusman R.M
        Cardiovascular effects of sildenafil citrate and recommendations for its use.
        Am J Cardiol. 1999; 84: 11N-17N
        • DeBusk R.F
        Sexual activity triggering myocardial infarction.
        JAMA. 1996; 275: 1447-1448
        • Drory Y
        • Shapira I
        • Fisman E.Z
        • Pines A
        Myocardial ischemia during sexual activity in patients with coronary artery disease.
        Am J Cardiol. 1995; 75: 835-837
        • Cheitlin M.D
        • Hutter Jr, A.M
        • Brindis R.G
        • et al.
        ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease.
        J Am Coll Cardiol. 1999; 33: 273-282
        • NIH Consensus Development Panel on Impotence
        NIH Consensus Conference.
        JAMA. 1993; 270: 83-90
        • Benet A.E
        • Melman A
        The epidemiology of erectile dysfunction.
        Urol Clin North Am. 1995; 22: 699-709
        • Webb D.J
        • Freestone S
        • Allen M.J
        • Muirhead G.J
        Sildenafil citrate and blood pressure–lowering drugs.
        Am J Cardiol. 1999; 83: 21C-28C
        • Kloner R.A
        • Jarow J.P
        Erectile dysfunction and sildenafil citrate and cardiologists.
        Am J Cardiol. 1999; 83: 576-582
        • Zusman R.M
        • Morales A
        • Glasser D.B
        • Osterloh I.H
        Overall cardiovascular profile of sildenafil citrate.
        Am J Cardiol. 1999; 83: 35C-44C
        • Jackson G
        • Benjamin N
        • Jackson N
        • Allen M.J
        Effect of sildenafil citrate on human hemodynamics.
        Am J Cardiol. 1999; 83: 13C-20C
        • Herrmann H.C
        • Chang G
        • Klugherz B.D
        • Mahoney P.D
        Hemodynamic effects of sildenafil in men with severe coronary artery disease.
        N Engl J Med. 2000; 342: 1622-1626
      2. Ishikura F, Ueda H, Hamada T, et al. Effects of sildenafil citrate (Viagra) on coronary flow in dogs with severe coronary stenosis [abstract 501285]. Circulation. 1999;100(suppl I):I-490.

      3. Traverse JH, Du R, Chen YJ, et al. Sildenafil (Viagra) improves coronary blood flow distal to a coronary stenosis during exercise. 72nd Scientific Sessions of the American Heart Association; November 7–10, 1999; Atlanta, Georgia. Abstract 1000.

        • Wallis R.M
        • Corbin J.D
        • Francis S.H
        • Ellis P
        Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro.
        Am J Cardiol. 1999; 83: 3C-12C
      4. Webb DJ, Muirhead GJ, Wulff M, Sutton A, Levi R, Dinsmore WW. Sildenafil citrate potentiates the hypotensive effects of nitric oxide donor drugs in male patients with stable angina. J Am Coll Cardiol. 2000;36:25–31.

      5. Viagra [package insert]. New York: Pfizer Inc, 1999.

      6. Data on file. New York: Pfizer Inc.

      7. Kloner RA, Brown M, Prisant LM, Collins M, for the Sildenafil Study Group. Efficacy and safety of Viagra (sildenafil citrate) in patients with erectile dysfunction taking concomitant antihypertensive therapy. Am J Hypertens. In press.

        • Conti C.R
        • Pepine C.J
        • Sweeney M
        Efficacy and safety of sildenafil citrate in the treatment of erectile dysfunction in patients with ischemic heart disease.
        Am J Cardiol. 1999; 83: 29C-34C
        • Olsson A.M
        • Persson C.A
        Efficacy and safety of Viagra (sildenafil citrate) in men with cardiovascular disease and erectile dysfunction.
        J Am Coll Cardiol. 2000; 35: 329
        • Morales A
        • Gingell C
        • Collins M
        • Wicker P.A
        • Osterloh I.H
        Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction.
        Int J Impot Res. 1998; 10: 69-74
        • Mittleman M.A
        • Glasser D.B
        • Orazem J
        • Collins M
        Incidence of myocardial infarction and death in 53 clinical trials of Viagra (sildenafil citrate).
        J Am Coll Cardiol. 2000; 35: 302
        • Speakman M.T
        • Kloner R.A
        Viagra and cardiovascular disease.
        J Cardiovasc Pharmacol Ther. 1999; 4: 259-267
        • Azarbal B
        • Mirocha J
        • Shah P.K
        • Cercek B
        • Kaul S
        Adverse cardiovascular events associated with the use of Viagra.
        J Am Coll Cardiol. 2000; 35: 553
        • Stief C.J
        • Uckert S
        • Becker A.J
        • et al.
        Effects of sildenafil on cAMP and cGMP in isolated human cavernous and cardiac tissue.
        Urology. 2000; 55: 146-150
      8. Lepore JJ, Pereira N, Maroo A, et al. Sildenafil is a pulmonary vasodilator which augments and prolongs vasodilatation by inhaled nitric oxide in patients with pulmonary hypertension. 72nd Scientific Sessions of the American Heart Association; November 7–10, 1999; Atlanta, Georgia. Abstract 107514. Circulation 2000;100(suppl I).

      9. Katz SD, Balidemaj K, Homma S, Wu H, Maybaum S. Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000;36(suppl I):845–851.

        • Montague D.K
        Penile prostheses.
        Urol Clin North Am. 1989; 16: 7-12
      10. Linet OI, Ogring FG, for the Alprostadil Study Group. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. N Engl J Med. 1996;334:873–877.

      11. Padma-Nathan H, Hellstrom WJG, Kaiser FE, et al, for the Medicated Urethral System for Erection (MUSE) Study Group. Treatment of men with erectile dysfunction with transurethral alprostadil. N Engl J Med. 1997;336:1–7.

      12. Hedlund H, Hedlund P. Pharmacotherapy in erectile dysfunction: agents for self-injection programs and alternative application models. Scand J Urol Nephrol Suppl.1996;179:129–138.